Fickenscher James E 4
4 · Zynerba Pharmaceuticals, Inc. · Filed Jan 25, 2023
Insider Transaction Report
Form 4
Fickenscher James E
Chief Financial Officer
Transactions
- Sale
Common Stock
2023-01-23$0.60/sh−17,769$10,622→ 154,736 total - Award
Common Stock
2023-01-24+170,000→ 324,736 total
Footnotes (2)
- [F1]This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
- [F2]The restricted stock award will fully vest in two installments, subject to continued employment with the Company through the applicable vesting date: 1/3 of the restricted stock will vest on February 1, 2024; and 2/3 of the restricted stock will vest on February 1, 2025.